vx-702

VX-702 is an investigational small molecule, orally available anti-cytokine therapy developed for the treatment of inflammatory diseases, primarily rheumatoid arthritis and acute coronary syndrome. It acts as a highly selective ATP-competitive inhibitor of p38 mitogen activated protein kinase (MAPK), with much higher potency against the p38α isoform than p38β. By inhibiting p38 MAPK, VX-702 suppresses the production of pro-inflammatory cytokines such as TNF-alpha, IL‑6, and IL‑1β. Clinical studies showed that while it reduced biomarkers like C-reactive protein and demonstrated some clinical activity in rheumatoid arthritis (including in combination with methotrexate), its efficacy was modest and transient. Development for these indications has been discontinued[1][2][3][4][5][6][7][8][9].

Other names

745833-23-2479543-46-9